Is Oscar Health Stock Still a Buy?

Oscar Health (OSCR) reported a profitable Q1 2025 with $275 million in net income on $3.05 billion in revenue, representing a 42% year-over-year increase, driven by operational improvements under new leadership and a reduced SG&A ratio. Despite this strong performance and potential tailwinds from proposed Medicare Part E legislation, analysts remain skeptical, resulting in a valuation that some believe undervalues the company's growth prospects and technology platform, presenting a contrarian investment opportunity.

Analysis

Oscar Health (NYSE: OSCR) has demonstrated a significant turnaround, achieving its first profitable year in 2024 and reporting strong Q1 2025 results with $275.3 million in net income, or $0.92 diluted EPS, on $3.05 billion in revenue. This performance represents a 42% year-over-year revenue growth and an EPS beat of over 14% against consensus estimates. Key drivers include operational tightening under new CEO Mark Bertolini, evidenced by a record-low SG&A ratio of 15.8% (a 260-basis point improvement) and a medical loss ratio (MLR) of 75.4%, leading to an expanded operating margin of 9.8%. As a digital-first insurer focused on ACA exchanges, Oscar now covers approximately 2 million members. The company faces a substantial growth opportunity with the proposed "Choose Medicare Act," which could introduce a Medicare Part E public option and potentially triple its addressable market. Despite the stock's 40% year-to-date surge to $19.40, analyst price targets hover around $18. Oscar trades at 14 times projected 2027 earnings, with its $4.8 billion market cap being less than half its current annual revenue, a valuation perceived as low for its growth compared to traditional insurers. The prevailing investment thesis suggests Oscar is mispriced as a conventional insurer rather than a high-growth technology company disrupting the healthcare insurance sector, even considering bear case arguments around customer complaints and network limitations.

Key Decisions for Investors

• Investors should assess Oscar Health's robust Q1 2025 financial performance, highlighted by 42% revenue growth and enhanced profitability, as indicative of a successful operational turnaround that may not be fully reflected in current analyst price targets.
• The proposed "Choose Medicare Act" presents a significant potential upside catalyst; therefore, monitoring legislative progress is crucial for evaluating Oscar's long-term growth trajectory and potential market expansion.
• Carefully weigh the company's high-growth profile and digital-first strategy against acknowledged risks such as customer service issues and technology execution, while noting the substantial operational leverage demonstrated through improved SG&A and MLR figures.
• Consider that an investment in Oscar Health aligns with a contrarian perspective, betting on the market's potential re-evaluation of the company as a technology-driven insurer rather than a traditional one, which could unlock significant value if its growth momentum and margin expansion continue.